12:00 AM
 | 
May 10, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Exisulind: Phase II/III

Columbia University researchers presented interim data from a 96-patient study showing a statistically significant reduction in mean prostate specific antigen (PSA) levels in the exisulind group...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >